Biogen (BIIB) Target Price Lifted to $358 at Jefferies

January 30, 2014 1:56 PM

Jefferies analyst Thomas Wei reiterated a Buy rating and raised his price target Biogen (NASDAQ: BIIB) from $318 to $358.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found